Cancer research leads to better outcomes
We study the full spectrum of cancer care, from prevention, screening and early detection to diagnosis, treatment and survivorship. The results of these studies are shared around the world to improve patient care. Our experts bring research and training experience from a variety of specialties, including:
- Early-Phase Therapeutics Program (EPTP)
- Phase II/III clinical trials
- Pre-clinical research
- Clinical quality projects
- Investigator-initiated trials
- Patient-reported outcome measures
- Partnership networks
- Survey research
Our Cancer Research Center partners with HealthPartners clinics and hospitals to integrate clinical research and quality improvement into routine care close to home. Our Early-Phase Therapeutics Program, also known as a Phase 1 Program, debuted in late 2015 at HealthPartners Cancer Center at Regions Hospital. These trials give patients local access to leading-edge treatment options that, in the past, required extensive travel to other health care organizations.
Our annual summary highlights recent work in cancer research.
We have numerous active trials:
- Cancer Research Center studies are available at certain HealthPartners clinics.
- Metro-Minnesota Community Oncology Research Consortium (MMCORC) studies are available at most participating cancer clinics in the Twin Cities metropolitan area.
- Daniel M. Anderson, MD, MPH*
- Michael Blazar, MD
- Cathleen Chen, MD
- Kurt C. Demel, MD, MBA
- Arek Z. Dudek, MD, PhD*
- Chitra Ganesan, MBBS
- Randy Hurley, MD
- Jeffrry P. Jaffe, MD
- Balkrishna Jahagirdar, MBBS
- Kendra Kubiak, MD
- Brenda Larson, MD
- Rachel E. Lerner, MD, MS*
- Steve E. McCormack, MD
- Mark R. Menge, MD
Making clinical trials more equitable
We are taking steps to ensure our work is equitable and supports the diverse communities we serve. We recently joined a project led by the American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC). We are one of 75 research sites invited to participate in an implicit bias training aimed at reducing barriers to clinical research opportunities. We will also pilot a self-assessment tool from ASCO and ACCC intended to improve policies, procedures, and programs that may inadvertently hinder participation in trials.